Cantor Fitzgerald Brokers Boost Earnings Estimates for VERV

Verve Therapeutics, Inc. (NASDAQ:VERV) – Equities researchers at Cantor Fitzgerald lifted their FY2025 EPS estimates for Verve Therapeutics in a research report issued to clients and investors on Thursday, May 15th. Cantor Fitzgerald analyst R. Bienkowski now expects that the company will earn ($2.16) per share for the year, up from their previous estimate of ($2.38). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Verve Therapeutics’ current full-year earnings is ($2.49) per share.

A number of other brokerages have also recently commented on VERV. Royal Bank of Canada cut their price target on shares of Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating for the company in a research note on Tuesday, March 4th. HC Wainwright lifted their price target on Verve Therapeutics from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, April 14th. Canaccord Genuity Group boosted their price target on Verve Therapeutics from $32.00 to $39.00 and gave the stock a “buy” rating in a research report on Tuesday, April 15th. Guggenheim upped their price objective on Verve Therapeutics from $18.00 to $24.00 and gave the company a “buy” rating in a research note on Tuesday, April 15th. Finally, William Blair reiterated an “outperform” rating on shares of Verve Therapeutics in a research note on Friday, February 21st. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Verve Therapeutics has a consensus rating of “Buy” and an average target price of $25.75.

Verve Therapeutics Stock Up 5.5%

NASDAQ:VERV opened at $4.61 on Monday. Verve Therapeutics has a twelve month low of $2.86 and a twelve month high of $9.31. The firm has a market capitalization of $410.95 million, a price-to-earnings ratio of -1.87 and a beta of 1.82. The stock’s 50 day moving average price is $4.71 and its two-hundred day moving average price is $5.84.

Verve Therapeutics (NASDAQ:VERV) last released its earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.36. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The business had revenue of $32.98 million for the quarter, compared to the consensus estimate of $7.13 million.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Verve Therapeutics by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 17,952 shares of the company’s stock valued at $101,000 after acquiring an additional 1,676 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Verve Therapeutics by 1.9% during the fourth quarter. Rhumbline Advisers now owns 111,203 shares of the company’s stock worth $627,000 after purchasing an additional 2,093 shares during the last quarter. Arizona State Retirement System increased its stake in shares of Verve Therapeutics by 15.8% in the fourth quarter. Arizona State Retirement System now owns 19,593 shares of the company’s stock valued at $111,000 after buying an additional 2,669 shares during the period. DekaBank Deutsche Girozentrale raised its holdings in Verve Therapeutics by 11.2% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 26,690 shares of the company’s stock valued at $122,000 after buying an additional 2,690 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Verve Therapeutics by 5.8% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 50,230 shares of the company’s stock worth $313,000 after acquiring an additional 2,742 shares during the last quarter. 97.11% of the stock is currently owned by institutional investors and hedge funds.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.